Pherecydes Pharma Logo

Pherecydes Pharma

Develops precision phage therapy to treat resistant bacterial infections.

ALPHE | PA

Overview

Corporate Details

ISIN(s):
FR0011651694
LEI:
894500LYT3UUN58X3I68
Country:
France
Address:
22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pherecydes Pharma is a biotechnology company that specializes in developing treatments for resistant bacterial infections. The company pioneers precision phage therapy, an approach that uses bacteriophage viruses (phages) to specifically target and combat harmful bacteria. This personalized therapeutic strategy is designed to treat severe and complicated infections that are unresponsive to conventional antibiotics. Founded in 2006, the company focuses on creating a portfolio of phages effective against critical bacterial pathogens. In June 2023, Pherecydes Pharma merged with Erytech Pharma to become Phaxiam Therapeutics, continuing its work in the fight against antimicrobial resistance.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Pherecydes Pharma and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-06-23 20:45
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 214.3 KB
2023-06-23 20:45
Post-Annual General Meeting Information
Inside Information / Other news releases
English 213.8 KB
2023-06-14 20:00
Legal Proceedings Report
Inside Information / Other news releases
English 197.1 KB
2023-06-14 20:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 200.6 KB
2023-06-08 07:30
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 297.3 KB
2023-06-08 07:30
Regulatory News Service
Inside Information / Other news releases
English 269.4 KB
2023-06-05 08:00
Legal Proceedings Report
Inside Information / Other news releases
English 198.4 KB
2023-06-05 08:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 192.1 KB
2023-06-02 20:00
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 152.4 KB
2023-05-23 23:43
M&A Activity
News releases during takeover bids / Takeover bids Other news releases
English 191.8 KB
2023-05-23 23:43
Registration Form
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 184.9 KB
2023-05-16 07:00
M&A Activity
Inside Information / Other news releases
English 224.2 KB
2023-05-16 07:00
M&A Activity
Informations privilégiées / Autres communiqués
French 216.3 KB
2023-05-11 18:00
Capital/Financing Update
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 200.6 KB
2023-04-27 18:00
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
French 195.2 KB

Automate Your Workflow. Get a real-time feed of all Pherecydes Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pherecydes Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.